Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) Invested Capital (2016 - 2025)

Historic Invested Capital for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $4.3 billion.

  • BeOne Medicines' Invested Capital fell 72.05% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year decrease of 72.05%. This contributed to the annual value of $3.5 billion for FY2024, which is 1720.4% down from last year.
  • Per BeOne Medicines' latest filing, its Invested Capital stood at $4.3 billion for Q3 2025, which was down 72.05% from $4.6 billion recorded in Q2 2025.
  • BeOne Medicines' 5-year Invested Capital high stood at $6.6 billion for Q4 2021, and its period low was $3.5 billion during Q4 2024.
  • Its 5-year average for Invested Capital is $4.6 billion, with a median of $4.3 billion in 2025.
  • Per our database at Business Quant, BeOne Medicines' Invested Capital surged by 5710.37% in 2021 and then plummeted by 2864.13% in 2022.
  • Over the past 5 years, BeOne Medicines' Invested Capital (Quarter) stood at $6.6 billion in 2021, then decreased by 28.64% to $4.7 billion in 2022, then fell by 9.73% to $4.2 billion in 2023, then decreased by 17.2% to $3.5 billion in 2024, then increased by 22.01% to $4.3 billion in 2025.
  • Its Invested Capital stands at $4.3 billion for Q3 2025, versus $4.6 billion for Q2 2025 and $4.3 billion for Q1 2025.